Skip to content

Statins and the apoB-lowering stack

Longevity medicationsdrug classDebated

Availability Prescription, repurposed

What it is

Statins and the drugs stacked with them all do one thing: lower apolipoprotein B, the protein wrapped around every artery-clogging particle in the blood. Statins cut cholesterol production in the liver. Ezetimibe blocks absorption in the gut. Bempedoic acid acts one step upstream of statins in the same pathway. PCSK9 inhibitors are injections that let the liver clear more particles from circulation.

Why people take it

Atherosclerosis is the leading cause of death and builds for decades before anything is felt, so the longevity case is prevention rather than repair: push apoB low, start early, hold it there. Protocol-driven programs set targets well below standard guidelines. Others arrive after a calcium score or a raised Lp(a) turned an abstract risk into a number.

How it's delivered

Statins, ezetimibe, and bempedoic acid are daily tablets. PCSK9 inhibitors are injections given every two weeks or, for one of them, twice yearly. All need a prescription and periodic lipid panels. Muscle complaints on statins are common in practice and mostly do not reproduce when trials blind which pill is which.

Where the evidence stands

Split down the middle. For people with established cardiovascular disease or high measured risk, this is among the best-evidenced drug classes in medicine: pooled trial data show each 1 mmol/L of LDL reduction cuts major vascular events by roughly a fifth, IMPROVE-IT added ezetimibe on top of a statin for a further 6 percent, CLEAR Outcomes cut events 13 percent with bempedoic acid in statin-intolerant patients, and the PCSK9 outcome trials landed near 15 percent. For low-risk people taking these drugs as a general longevity measure, the evidence is thinner and genuinely contested: absolute benefit shrinks as baseline risk falls, mortality effects in primary prevention are small, and STAREE, the trial testing a statin in healthy adults over 70 for disability-free survival, has not yet reported.

Estimated cost

  • Generic statins, often under $15/mo
  • $15–$40/mogeneric ezetimibe
  • $400–$500/mobempedoic acid, brand only
  • $500–$600/moPCSK9 inhibitors before coverage
  • Usually covered when there is a cardiovascular indication

Who offers it

  • ProtocolAttia apoB-lowering protocol
  • Cliniclongevity clinics with lipid management
  • Telehealthlongevity Rx platforms
How we know

Observed in provider menus on our last research pass; each listing is stamped when verified. We may be compensated when you contact providers through Longevity.io; payment never affects ranking.

Go deeper

No dedicated statin guide yet. Our blood biomarkers guide covers apoB, LDL, and Lp(a), what the numbers mean, and how risk is actually estimated.

Explore blood biomarkers for longevity

Longevity.io is for educational purposes only and is not medical advice. Whether any of these drugs belongs in a plan depends on measured risk, and that is a conversation for a clinician who knows the whole picture. Confirm eligibility, services, and pricing directly with any provider.

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint